SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Nelson Mandela — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientNelson Mandela
Date of birth1918-07-18
IdentifiersMRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718
Document date2001-04-14
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week follow-up after the prostate cancer diagnosis; staging result; radiation oncology seen today. [S]

History of Present Illness

Mr. Mandela returns five weeks after his first visit. The PSMA PET/CT two weeks ago showed uptake only in the prostate, with no spread to lymph nodes or bone. He had his DXA scan this morning and then saw Dr. van Zyl of radiation oncology, who went through observation, radiotherapy with short-term androgen deprivation, and surgery with him. He chose radiotherapy to the prostate with six months of androgen deprivation. He starts bicalutamide today and will have his first leuprolide injection at the radiation oncology clinic in one week. Before starting, he was told the expected effects of androgen deprivation (hot flashes, tiredness, loss of libido and erections, weight gain, bone loss, and changes in mood or memory) and how they are monitored. His urinary symptoms are unchanged and mild. He has no bone pain, weight loss, or breathlessness. He starts vitamin D today for the low level found at the first visit. [S]

ElementDetail
StagingPSMA PET/CT: disease confined to the prostate (N0 M0)
DecisionRadiotherapy with six months of androgen deprivation, after radiation oncology consultation today
Starting todayBicalutamide 50 mg daily for four weeks; cholecalciferol 1000 units daily
Next stepFirst leuprolide injection in one week at radiation oncology

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fatigue, weight loss, or night sweats
GenitourinaryPositiveMild urinary frequency, unchanged; no blood in the urine
MusculoskeletalNegativeNo bone or back pain
RespiratoryNegativeNo cough or breathlessness
PsychiatricNegativeMood good; PHQ-2 score 0

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2001-04-14 to 2001-05-12completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2001-04-14activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2001-04-14Body height183cmS
2001-04-14Body weight80.4kgS
2001-04-14Body mass index (BMI) [Ratio]24kg/m2S
2001-04-14Systolic blood pressure130mm[Hg]S
2001-04-14Diastolic blood pressure76mm[Hg]S
2001-04-14Heart rate66/minS
2001-04-14Respiratory rate14/minS
2001-04-14Body temperature36.7CelS
2001-04-14Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-04-14DXA Femur [T-score] Bone density-1.4{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisLowS
2001-04-14DXA Lumbar spine [T-score] Bone density-0.6{T-score}-1.0 or higher is normal; -2.5 or lower is osteoporosisNormalS
2001-04-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2001-04-14; see the Vital Signs section. [S]

SystemFinding
GeneralWell
CardiovascularRegular rhythm; blood pressure 130/76 mm Hg; no ankle swelling
AbdomenSoft; bladder not palpable
MusculoskeletalNo spinal tenderness

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA before treatmentAt diagnosis, then every 3 to 6 months on androgen deprivationUp to date6.4 ng/mL at the first visit; next on androgen deprivation in three months
LaboratoryTestosteroneBaseline, then every 3 to 6 months on androgen deprivation (target below 50 ng/dL)Up to date412 ng/dL at the first visit, before treatment; recheck in three months
LaboratoryHemoglobin A1c or fasting glucose, and lipid panelBaseline and yearly on androgen deprivationUp to dateA1c 5.5 percent, glucose 94 mg/dL, LDL 112 mg/dL at the first visit; next in one year
LaboratoryCalcium and 25-hydroxyvitamin DBaseline and periodically on androgen deprivationDueCalcium 9.4 mg/dL and vitamin D 26 ng/mL at the first visit; supplement starts today; vitamin D recheck in three months
ImagingBone density (DXA)Baseline before androgen deprivation, then every 1 to 2 yearsCompleted todayFemoral neck T-score -1.4 (low bone mass); lumbar spine -0.6 (normal); hip fracture risk below the treatment threshold
ImagingPSMA PET/CT stagingOnce, for unfavorable intermediate or high riskUp to dateTwo weeks ago: no nodal, bone, or visceral disease
ExaminationBlood pressure and cardiovascular assessmentEvery visit on androgen deprivationCompleted today130/76 mm Hg; no chest pain or breathlessness; baseline before treatment
SurveyDistress and depression screen (PHQ-2)At diagnosis and at intervalsCompleted todayPHQ-2 score 0
SurveyUrinary symptoms (IPSS)Baseline before treatment, then every follow-up visitUp to dateIPSS 7 (mild) at the first visit; no change today
SurveySexual functionBaseline before treatment and periodicallyCompleted todayReviewed before androgen deprivation; the expected effects were explained
SurveyCognitionPeriodically on androgen deprivationDueCognitive screen at the annual wellness visit in about eight weeks
Medication safetyHot flashes and fatigueEvery visit on androgen deprivationNot indicatedAndrogen deprivation not yet started; counseled on what to expect
Medication safetyTestosterone flare protectionWhen starting a GnRH agonistCompleted todayBicalutamide starts today, one week before leuprolide, and continues for four weeks
ReferralRadiation oncologyOnce, then through treatmentCompleted todaySeen today; recommendations in the consultation note
Self-managementPhysical activity, calcium intake, and no tobaccoEvery visitCompleted todayWalking every morning; resistance exercise added; dietary calcium reviewed

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)

Follow-up: Leuprolide at radiation oncology in one week. Annual wellness visit in eight weeks. Primary care follow-up in three months with PSA, testosterone, and vitamin D. Next scheduled visit 2001-06-09: subsequent annual wellness visit. [S]